LAPADULA GIUSEPPE

Lapadula, G., Soria, A., Antolini, L., Rugova, A., Colella, E., Sabbatini, F., et al. (2026). HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 81(3) [10.1093/jac/dkag045]. Detail

Micheli, G., Mondi, A., Roen, A., Taramasso, L., Luchetti, I., Mazzotta, V., et al. (2026). Did the COVID-19 pandemic shift the landscape of late HIV diagnosis?. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 165(April 2026) [10.1016/j.ijid.2026.108437]. Detail

D'Arminio Monforte, A., Lentini, N., Tavelli, A., Rusconi, S., Sozio, F., Guida, A., et al. (2026). Proportion of newly diagnosed persons with HIV with HIV-RNA greater than/equal to 500 000 copies/mL in 2018–2023 in Italy: data from the ICONA Foundation Cohort Study. CLINICAL MICROBIOLOGY AND INFECTION [10.1016/j.cmi.2026.01.007]. Detail

Rugova, A., Ghilardi, G., Colella, E., Squillace, N., Cappelletti, A., Sabbatini, F., et al. (2025). Unexpected HBV reactivation following discontinuation of antiviral prophylaxis in immunosuppressed subjects with previous HBV exposure. In Abstracts from the 17° Italian Conference on AIDS and Antiviral Research (pp.145-146) [10.1136/sextrans-icar-2025.146]. Detail

Mezzadri, L., Soria, A., Ranzani, A., Malandrin, S., Sabbatini, F., Limonta, S., et al. (2025). Hepatitis B core antibody positivity is not associated with risk of transaminase elevation following switch to dual antiretroviral therapy. AIDS, 39(10), 1344-1352 [10.1097/QAD.0000000000004227]. Detail